Efficacy of the Entire Papilla Preservation Technique With and Without the Use of L-PRF as a Regenerative Material for the Treatment of Infrabony Defects
Launched by UNIVERSIDAD DE LOS ANDES, CHILE · Nov 15, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to treat gum disease, specifically the use of a special material called L-PRF (which is made from the patient's own blood) along with a technique that helps preserve healthy gum tissue during surgery. The researchers want to find out if using L-PRF can improve healing and results in patients with specific types of gum defects compared to not using it. They will look at both clinical results, like how deep the gum pockets are after treatment, and radiographic results, which involve taking X-rays to see how the bone around the teeth is healing.
To participate in this trial, patients should be diagnosed with gum disease and have certain conditions, such as deep gum pockets that didn't improve after initial treatment. However, individuals with serious health issues like uncontrolled diabetes or certain bone-related diseases, as well as pregnant or breastfeeding women, cannot take part. Participants will undergo surgery and then report their pain levels after 1 day and 7 days post-operation. The study will involve 30 patients, half using L-PRF and half not, and their progress will be monitored for six months to see how well the treatments work.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients diagnosed with periodontal disease (loss of interproximal clinical attachment loss in 2 non-adjacent teeth or clinical attachment loss of ≥3mm associated with a PD \>3 mm in two or more teeth) will be included.
- • After re-evaluation (6 weeks after non-surgical periodontal therapy) presented residual probing depths equal to or greater than 6 mm.
- • Residual pocket is associated with interproximal intrabony periodontal defects of at least 2 walls, with a depth ≥ 3 mm and an angulation ≤ 40º determined on a periapical radiograph.
- Exclusion Criteria:
- • Patients with an underlying decompensated pathology such as diabetes and hypertension.
- • Patients taking medications that interfere with the healing process such as bisphosphonates.
- • Patients with diseases that alter bone metabolism such as osteoporosis.
- • Pregnant or breastfeeding women.
About Universidad De Los Andes, Chile
Universidad de los Andes in Chile is a prestigious academic institution renowned for its commitment to advancing research and innovation in the healthcare sector. As a clinical trial sponsor, the university leverages its robust multidisciplinary expertise and state-of-the-art facilities to facilitate cutting-edge medical research. The institution focuses on enhancing patient care and outcomes through rigorous clinical studies, fostering collaboration among healthcare professionals, researchers, and industry partners. With a strong emphasis on ethical standards and regulatory compliance, Universidad de los Andes strives to contribute significantly to the global medical community and improve health solutions in Chile and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Santiago, San Bernardo, Chile
Patients applied
Trial Officials
Andreas G Anwandter, DDS
Principal Investigator
Universidad de Los Andes
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported